Pacira BioSciences Unveils Promising 104-Week Study Results
Exciting Developments in Osteoarthritis Treatment
Pacira BioSciences, Inc. (NASDAQ: PCRX), a pioneer in non-opioid pain management solutions, has announced significant data regarding its gene therapy candidate, PCRX-201. This therapy aims to address moderate to severe osteoarthritis of the knee, and the results have generated considerable anticipation within the medical community.
Upcoming Presentation at Major Conference
The data supporting PCRX-201 will be prominently featured at the American College of Rheumatology’s ACR Convergence annual meeting, scheduled for mid-November. This venue provides an exceptional platform for sharing breakthroughs that could shape the future of osteoarthritis treatment.
Key Presentation Details
The presentation, titled "Sustained Clinical Effects After a Single Intra-articular Injection of PCRX-201 for Moderate-to-Severe Osteoarthritis of the Knee", is set to be delivered by esteemed Rheumatologist Dr. Stanley Cohen. This session will highlight the sustained clinical effects observed with this innovative therapy.
Date and Timing
Healthcare professionals and attendees can mark their calendars for this enlightening session on Sunday, November 17, from 10:30 am to 12:30 pm EST. This is an invaluable opportunity to learn about advancements in treatment protocols and patient outcomes.
Understanding PCRX-201’s Mechanism
PCRX-201 is designed for targeted administration at the site of knee joint pain, differentiating it from systemic gene therapies. It utilizes an inducible promoter to allow the production of interleukin-1 receptor antagonist (IL-1Ra), a natural anti-inflammatory protein. By reducing IL-1 signaling—which is correlated with osteoarthritis—PCRX-201 aims to alleviate pain while potentially decelerating the disease's progression.
Regulatory Milestones Achieved
In recent developments, PCRX-201 has received the prestigious Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA). This recognition underscores the therapy's potential and ensures that the development process will be supported with FDA guidance for expedited review pathways.
European Regulation Success
Furthermore, the European Medicines Agency granted advanced therapy designation to PCRX-201, indicating its acceptance in international regulatory discussions and promising avenues for market approval across borders.
About Pacira BioSciences
Pacira BioSciences is at the forefront of providing innovative pain management solutions without opioids. Among its approved products are EXPAREL, a long-acting local anesthetic for post-surgical pain relief; ZILRETTA, a treatment for knee pain due to osteoarthritis; and ioveraº, a device that offers drug-free pain control using precise cold therapy. Each of these therapies represents Pacira's commitment to enhancing patient quality of life by providing alternative pain management options.
Conclusion
The upcoming presentation of PCRX-201 at the ACR Convergence meeting marks a pivotal moment for both Pacira BioSciences and the treatment of osteoarthritis. The innovative approaches and technologies being developed by Pacira highlight the company's mission to transform patient lives through superior non-opioid therapies.
Frequently Asked Questions
What is PCRX-201?
PCRX-201 is a locally administered gene therapy aimed at treating moderate to severe osteoarthritis in the knee.
What will be presented at the ACR Convergence meeting?
The presentation will cover the sustained clinical effects of a single injection of PCRX-201 in patients suffering from osteoarthritis of the knee.
Who is the presenter for this data?
The data will be presented by Dr. Stanley Cohen, a board-certified rheumatologist.
What is RMAT designation?
Regenerative Medicine Advanced Therapy (RMAT) designation supports expedited development and review by the FDA for therapies showing promise in treating serious conditions.
How does PCRX-201 work?
PCRX-201 produces an anti-inflammatory protein that targets the source of inflammation and pain in the osteoarthritic joint.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Septerna Initiates Promising Clinical Trial for SEP-786
- Marqeta Sets Date for Third Quarter Financial Results Call
- LakeShore Biopharma Shares Consolidation Meeting Results Revealed
- Hinen Unveils Innovative Energy Storage Solution for Homes
- iHuman Inc. Unveils Q2 2024 Financial Results: Growth Insights
- Celebrating Mountain Tourism: Conference Unveils New Heights
- Intercontinental Exchange Forecast Shows Promising Growth Ahead
- Three Promising Stocks to Consider Amid Dow's Record High
- Hinen Unveils Innovative Home Energy Storage Solutions Worldwide
- IDEAYA Biosciences Expands Its Team with Incentive Stock Grants
Recent Articles
- IES Holdings Welcomes John Louis Fouts to Its Board
- INKmune™ Shows Promising Results in NK-Cell Therapy Trials
- Ultragenyx Unveils Key Setrusumab Presentations at Major Meeting
- Teledyne Unveils Innovative AI-Powered Camera for Industry
- Fairfax Financial Plans to Buy Back Voting and Preferred Shares
- Fairfax India Plans Significant Normal Course Issuer Bid Initiative
- Growing Demand for Bicycle Accessories Expected Through 2034
- Cerro de Pasco Resources Secures $3 Million Investment Boost
- Tritent International Corp. and Burst Technologies Join Forces
- Alliance Trust PLC Reports Latest Net Asset Value Figures
- iSpecimen Secures Funding and Welcomes New Leadership Team
- Janover Inc Launches AI Tools to Transform Insurtech Sector
- Exciting Partnership Between BNB Chain and UXUY Wallet Emerges
- Three Dividend-Paying Real Estate Stocks to Consider for 2024
- Renewable Land Expands Renewable Energy Footprint in Ohio
- Understanding the Impact of Falling Mortgage Rates on Homebuyers
- Exro Forms Strategic Partnership with Stellantis for EV Innovation
- MCF Energy's Welchau-1 Well: Key Insights and Upcoming Tests
- Scottie Resources Completes 10,000 Metre Drill Program Successfully
- Theratechnologies Announces Q3 2024 Financial Results Plans
- Valmet Announces Second Dividend Payment for 2023 Success
- Baxter Unveils Innovative Pulmonary System for Lung Care
- Harnessing Grid-Scale Battery Energy Storage for Tomorrow's Energy Needs
- iSpecimen Announces Strategic Changes and Loan Acquisition
- Transforming Business Growth with AI: The Future of Strategic Decisions
- Evaxion Biotech Partners with MSD to Develop Vaccine Candidates
- Hallcon Expands Leadership Team with Rob Antoniak's Expertise
- Lilium Jet Launches New Era of Electric Aviation in Texas
- Rosenblatt Upgrades Micron's Stock: Promising Future Ahead
- Wiley's Dividend Growth: A Testament to Financial Stability
- DocGo Welcomes New CIO to Enhance Healthcare Technology Strategy
- Truist Securities Endorses First Solar's Bright Future
- Benchmark Affirms Buy Rating on Flutter Entertainment Amid Growth Plans
- Truist Ups Kratos Defense Price Target, Strong Growth Ahead
- Sonos Faces Challenges After Double Downgrade by Analysts
- Jabil Circuit Inc. Reports Strong Fiscal Q4 Earnings and Growth
- S&P 500 Reaches New Heights Fueled by Chinese Stimulus
- Eco-Friendly Paper Tubes Market Set to Reach USD 2.6 Billion
- Investor Enthusiasm Grows Amid Promising Economic Trends
- Bicycle Accessories Market Growth: Projecting US$ 36 Billion by 2034
- Verano Unveils New Zen Leaf™ Arcadia Location in Phoenix Area
- Autonomix Medical Unveils New CEO Corner Segment Focused on Pain Management
- Exciting New Zinc, Lead, and Silver Drilling Results Unveiled
- iSpecimen Strengthens Position with Loan and New Directors
- Strategic Merger of Tritent International and Burst Technologies
- Theratechnologies Set to Reveal Q3 2024 Financial Insights
- Real Brokerage Survey Reveals Agent Resilience Post-NAR Changes
- Lilium's Innovative Jet Launches in Houston With Key Partnerships
- Capstan Therapeutics Unveils Breakthrough Data on CPTX2309
- Kelly Engineering Shines as a Leader in Staffing for 2024